Myrbetriq (Mirabegron) Improved BPH Urinary Symptoms in Men Already on Tamsulosin (Flomax)

Symptoms of overactive bladder affect patients’ quality of life. Adding mirabegron therapy to treat overactive bladder symptoms in older men already taking Tamsulosin for underlying benign prostatic hyperplasia is considered to be well-tolerated and safe. To evaluate the safety and efficacy of mirabegron vs. placebo in men with OAB already on Tamsulosin for underlying benign prostatic hyperplasia, a 12-week, randomized, large-scale trial known as PLUS trial was conducted. Learn more about the benefits of combination therapy from the best Canadian online pharmacy. 

About Plus Study

The Phase 4 PLUS study comprised a placebo-controlled, double-blind, 4-week run-in period and a 12-week randomized treatment period. The multi-centre research based in North America and Europe randomized 715 male patients more than 40 years of age. The trial was run with the objective of evaluating the safety and efficacy of mirabegron vs. placebo as an add-on therapy for treating symptoms of an overactive bladder in men already taking Tamsulosin for BPH Urinary Symptoms. At the start of the study, patients were divided into two groups: one group of 352 men received 25 mg of mirabegron, while the other group comprising 354 men received a placebo. 

After four weeks, the dosage was increased to 50 mg of mirabegron or placebo equivalent. More overall side effects were seen in patients taking Tamsulosin with a placebo, but more drug-related side effects were noted in patients taking the medication with Mirabegron. Most of the side effects ranged from mild to moderate. However, three patients reported serious drug-related side effects, including heart and stroke-related issues. The most common side effects were hypertension, headache, and nasopharyngitis. Few patients experienced urinary retention, with only two patients taking Tamsulosin with mirabegron needed catheterization. No significant changes in blood pressure, pulse rate, or heart measurements were observed. There were no meaningful changes in bladder emptying or urine flow rate. 

Results of the PLUS Trial 

The 12-week trial results demonstrated that the addition of Myrbetriq to Flomax significantly improved symptoms related to urinary urgency and frequency in men already on Tamsulosin. It also indicated that Myrbetriq’s addition to the medication significantly improved symptoms related to urinary urgency and frequency in the patients. This combination therapy could be considered a more robust approach for those who have not achieved sufficient relief from tamsulosin alone. However, as with any medication or combination therapy, it is essential for patients to discuss their options with healthcare providers, who can tailor treatment plans based on individual symptoms and health profiles.

Indication and Usage of Myrbetriq 

Mirabegron (Myrbetriq) is a beta-3 adrenergic agonist that is indicated for an overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequent urination. It is prescribed for:

• Myrbetriq is used to treat overactive bladder in adults with symptoms of urgency, leakage and frequency. It works by relaxing the bladder muscle to improve the storage capacity of the bladder, reducing the symptoms of OAB.
• Neurogenic detrusor overactivity (NDO) in pediatric patients aged more than three years and weighing 35 kg or more.

Benefits of Myrbetriq

1. Provides relief from overactive bladder symptoms- Myrbetriq can be used alone or in combination with solifenacin succinate to treat OAB symptoms, such as frequent or urgent urination and urinary incontinence. Myrbetriq relaxes the muscles of the urinary bladder, reducing bladder spasms. 
2. Used in treatment for neurogenic detrusor overactivity- Myrbetriq is also used in pediatric patients of 3 years old or above to treat neurogenic detrusor overactivity (NDO). NDO-related urinary incontinence occurs due to permanent nerve damage from conditions like multiple sclerosis or spinal injury. 

Safety Information Regarding its Use 

Myrbetriq is contraindicated for use in patients who have severe uncontrolled hypertension or known hypersensitivity to mirabegron or any other ingredient present in the medication. If you have Myrbetriq, when used alone or in combination with solifenacin, succinate can increase blood pressure in adults. If someone already has hypertension, taking Myrbetriq may worsen your condition. In some patients, it has been linked to urinary retention, especially in those patients who have bladder outlet obstruction or those taking muscarinic antagonist medications for overactive bladder. Angioedema of the face, lips, tongue, and/or larynx has been reported as Myrbetric. It may occur after the first or after taking multiple doses of the medication. If swelling occurs, you should discontinue taking the drug, and appropriate therapy should be initiated to ensure a clear airway. 

Potential Side Effects of Myrbetiq 

Like every other medication, Myrbetriq also has a risk of unwelcome side effects. These side effects usually go away on their own and do not require medical attention. It is important to note that the side effects of a drug can depend on your age, medical history and other medications you take. Some of the common side effects of Myrbetriq may include: 

• Diarrhea 
• Urinary tract infection (UTI)
• Back pain
• Dizziness 
• Constipation
• Dry mouth 
• Headache 
• Joint pain
• Rapid heartbeat
• Nausea 
• Swelling in your nasal passages and throat
• Symptoms of common cold

However, if these symptoms continue after some weeks or have become bothersome, contact your doctor at once. Myrbetriq tablets may also cause adverse effects such as high blood pressure, severe allergic reactions and urinary retention. If you experience signs and symptoms of allergic reaction such as redness, itching and rash, report them to your doctor even if they are not serious. They may recommend you discontinue the medication and take an alternative to Myrbetriq to treat your condition. If the symptoms are left untreated, they can lead to severe fatal conditions.

Conclusion 

In conclusion, Myrbetriq and Tamsulosin may offer benefits for individuals experiencing urinary symptoms associated with benign prostatic hyperplasia (BPH). However, it’s essential to consult with a healthcare professional for personalized advice and treatment options. This combination therapy represents a valuable option for men seeking relief from lower urinary tract symptoms such as urinary urgency and frequency. The addition of mirabegron to Tamsulosin significantly improved symptoms of BPH in men already taking Flomax, it is crucial to be aware of the potential risks associated with its usage. Consult your doctor or healthcare provider for personalized guidance.